https://mindmedicinelaw.com/briefing/psychologists-seek-apa-psychedelic-science-division-policy-and-practice-implicat-20261106-56944The Psychedelic Journalen2026-11-06T22:08:03.118449+00:00Psychologists Seek APA Psychedelic Science Division: Policy and Practice Implicationsapa psychedelic division, psychologists petition, psychedelic research policy, clinical training psychedelics, institutional acceptance psychedelics, ethical standards psychedelic care, research funding psychedelics, professional legitimacy psychologyhttps://mindmedicinelaw.com/briefing/audit-finds-mdma-and-psilocybin-trials-rarely-test-trim-hypothesis-3-at-12-month-20261105-56853The Psychedelic Journalen2026-11-06T22:08:31.080598+00:00Audit Finds MDMA and Psilocybin Trials Rarely Test TRIM Hypothesis 3 at 12 Monthsmdma-assisted therapy, psilocybin therapy, randomized controlled trials, trauma-resilience integration model, trim hypothesis 3, long-term follow-up, comparator arms, clinical evidence gaps, psychedelic research, regulatory standardshttps://mindmedicinelaw.com/briefing/psilocybin-vs-ibogaine-rural-health-systems-face-strategic-choice-20261105-56832The Psychedelic Journalen2026-11-06T22:08:17.519080+00:00Psilocybin vs Ibogaine: Rural Health Systems Face Strategic Choicepsilocybin therapy, ibogaine, rural health systems, opioid use disorder, behavioral health, fda regulation, clinical evidence, psychedelic-assisted therapy, service delivery modelshttps://mindmedicinelaw.com/briefing/psilocybin-s-astrocytic-modulation-of-nucleus-accumbens-mechanism-and-implicatio-20261105-56833The Psychedelic Journalen2026-11-06T22:07:18.107581+00:00Psilocybin’s Astrocytic Modulation of Nucleus Accumbens: Mechanism and Implicationspsilocybin, nucleus accumbens, astrocytes, GABA homeostasis, NFATc4, ALDH5A1, psychedelic mechanism, translational neuroscience, mood disorders, addiction researchhttps://mindmedicinelaw.com/briefing/epa-snurs-under-tsca-implications-for-psychedelic-research-supply-chains-20261105-56611The Psychedelic Journalen2026-11-05T15:05:34.769044+00:00EPA SNURs Under TSCA: Implications for Psychedelic Research Supply Chainsepa snur, tsca regulation, psychedelic research compliance, chemical supply chain, significant new use rule, research chemical regulation, regulatory risk, drug law interface, laboratory compliance, chemical notificationhttps://mindmedicinelaw.com/briefing/ketamine-s-impact-on-emotional-evidence-integration-new-insights-for-translation-20261104-56869The Psychedelic Journalen2026-11-06T22:09:05.305468+00:00Ketamine’s Impact on Emotional Evidence Integration: New Insights for Translational Psychiatryketamine, emotional evidence integration, affective disorders, clinical trial design, nmda receptor antagonist, environmental volatility, translational psychiatry, neurocognitive mechanisms, psychedelic researchhttps://mindmedicinelaw.com/briefing/oral-ketamine-for-resistant-depression-evidence-protocols-and-policy-gaps-20261104-56877The Psychedelic Journalen2026-11-06T22:08:53.538518+00:00Oral Ketamine for Resistant Depression: Evidence, Protocols, and Policy Gapsoral ketamine, treatment-resistant depression, suicidality, dosing protocols, randomized controlled trials, psychiatric policy, adverse effects, clinical guidelines, regulatory approvalhttps://mindmedicinelaw.com/briefing/phase-2-trial-itbs-extends-ketamine-response-in-trd-patients-20261104-56879The Psychedelic Journalen2026-11-06T22:08:42.690902+00:00Phase 2 Trial: iTBS Extends Ketamine Response in TRD Patientstreatment-resistant depression, ketamine, intermittent theta burst stimulation, iTBS, clinical trial, phase 2, brain connectivity, neuromodulation, combination therapy, fMRIhttps://mindmedicinelaw.com/briefing/oral-ketamine-in-burn-wound-care-clinical-evidence-and-policy-outlook-20261104-56739The Psychedelic Journalen2026-11-05T22:06:03.473441+00:00Oral Ketamine in Burn Wound Care: Clinical Evidence and Policy Outlookoral ketamine, burn wound care, pain management, acute care, clinical protocols, off-label use, opioid alternatives, regulatory policy, hospital formulary, NMDA antagonisthttps://mindmedicinelaw.com/briefing/psilocybin-assisted-therapy-trial-in-advanced-lung-cancer-patients-us-2026-20261104-56676The Psychedelic Journalen2026-11-05T15:05:51.895802+00:00Psilocybin-Assisted Therapy Trial in Advanced Lung Cancer Patients (US, 2026)psilocybin therapy, lung cancer depression, clinical trial 2026, palliative care psychedelics, FDA policy, oncology mental health, psychedelic-assisted therapy, insurance coverage, patient safety, end-of-life carehttps://mindmedicinelaw.com/briefing/discovery-of-naadp-lysosomal-pathway-in-5-ht2a-psychedelic-signaling-20261103-56881The Psychedelic Journalen2026-11-06T22:07:41.174356+00:00Discovery of NAADP-Lysosomal Pathway in 5-HT2A Psychedelic Signaling5-ht2a receptor, naadp, lysosomal calcium, psychedelic mechanism, neuroplasticity, hallucinogenic effects, drug development, clinical translation, intracellular signalinghttps://mindmedicinelaw.com/briefing/psilocybin-therapy-for-cancer-distress-systematic-review-insights-20261103-56838The Psychedelic Journalen2026-11-06T22:07:29.939087+00:00Psilocybin Therapy for Cancer Distress: Systematic Review Insightspsilocybin-assisted therapy, cancer-related distress, systematic review, existential distress, depression and anxiety, palliative care, clinical trial design, adverse events, regulatory policy, psychedelic researchhttps://mindmedicinelaw.com/briefing/compass-pathways-to-submit-psilocybin-therapy-for-depression-in-eu-and-us-20261103-56677The Psychedelic Journalen2026-11-05T15:05:12.584856+00:00Compass Pathways to Submit Psilocybin Therapy for Depression in EU and UScompass pathways, psilocybin therapy, depression treatment, fda approval, ema submission, clinical trials, psychedelic medicine, market access, drug regulation, mental health policyhttps://mindmedicinelaw.com/briefing/psychedelic-pharmacotherapy-for-gambling-disorder-evidence-and-gaps-20261031-56454The Psychedelic Journalen2026-11-05T15:06:59.694082+00:00Psychedelic Pharmacotherapy for Gambling Disorder: Evidence and Gapsgambling disorder, psychedelics, psilocybin, ketamine, opioid antagonists, naltrexone, clinical trials, behavioral addiction, pharmacotherapy, regulatory guidancehttps://mindmedicinelaw.com/briefing/fireside-project-s-25-000-psychedelic-support-dataset-us-evidence-for-policy-and-20261030-56851The Psychedelic Journalen2026-11-06T22:07:51.965600+00:00Fireside Project's 25,000+ Psychedelic Support Dataset: US Evidence for Policy and Practicefireside project, psychedelic support, harm reduction, peer support dataset, psilocybin use, cannabis distress, public health policy, nonclinical psychedelic use, volunteer training, epidemiologyhttps://mindmedicinelaw.com/briefing/iowa-grants-ayahuasca-religious-exemption-legal-pathways-and-precedent-20261029-56679The Psychedelic Journalen2026-11-05T15:06:16.112715+00:00Iowa Grants Ayahuasca Religious Exemption: Legal Pathways and Precedentayahuasca, iowa, religious exemption, entheogen law, rfra, psychedelic policy, dea, church use, legal precedent, schedule ihttps://mindmedicinelaw.com/briefing/systematic-review-psychedelics-and-psychosis-risk-1984-2025-20261027-56768The Psychedelic Journalen2026-11-05T22:05:07.862575+00:00Systematic Review: Psychedelics and Psychosis Risk (1984–2025)psychedelics, psychosis risk, systematic review, clinical trial safety, public health policy, screening protocols, adverse event reporting, neuroscience, regulatory guidancehttps://mindmedicinelaw.com/briefing/ketamine-s-expanding-medical-profile-policy-and-research-implications-global-202-20261023-56749The Psychedelic Journalen2026-11-05T22:05:31.325598+00:00Ketamine’s Expanding Medical Profile: Policy and Research Implications (Global, 2026)ketamine, analgesic mechanisms, psychiatric effects, antitumour activity, immunomodulation, clinical trials, regulatory policy, off-label use, risk-benefit assessment, biomarker integrationhttps://mindmedicinelaw.com/briefing/ketamine-derivative-s-antidepressant-effects-via-adenosine-ncbi-study-20261022-56756The Psychedelic Journalen2026-11-05T22:05:48.350792+00:00Ketamine Derivative’s Antidepressant Effects via Adenosine: NCBI Studyketamine derivative, adenosine signaling, antidepressant mechanism, rapid-acting antidepressants, mood disorders, clinical trials, ncbi study, nmda antagonism, drug development, psychiatric therapeuticshttps://mindmedicinelaw.com/briefing/cost-effectiveness-of-ketamine-versus-ect-in-us-depression-care-20261022-56780The Psychedelic Journalen2026-11-05T22:04:52.280854+00:00Cost-Effectiveness of Ketamine Versus ECT in US Depression Careketamine, electroconvulsive therapy, treatment-resistant depression, cost-effectiveness, insurance coverage, clinical guidelines, mental health policy, health economics, psychiatric interventions